Physician profile
Suresh Sureddi
NPI 1710932561
$2,175,157.24
in general payments reported to CMS, 2019-2025
26 companies · $402K in 2025
The $402K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379K · 2020: $112K · 2021: $175K · 2022: $323K · 2023: $415K · 2024: $370K · 2025: $402K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $767K · Consulting Fee: $174K · Travel and Lodging: $132K · Honoraria: $90K · Food and Beverage: $24K · Education: $58.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $766,987.62 |
| Consulting Fee | $173,694.00 |
| Travel and Lodging | $132,033.04 |
| Honoraria | $89,779.00 |
| Food and Beverage | $24,030.30 |
| Education | $58.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $562,271.83 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $338,881.06 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $331,583.07 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $291,459.98 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $250,281.97 | 2022-2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $156,390.43 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Allergan, INC. | $143,030.89 | 2019-2020 | |
| Abbvie INC. | $47,112.12 | 2021-2025 | Vraylar |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19,297.20 | 2019-2025 | Abilify Asimtufii, Abilify Maintena |
| Janssen Research & Development, LLC | $8,265.40 | 2019 | |
| Sunovion Pharmaceuticals INC. | $7,977.09 | 2019-2022 | |
| H. Lundbeck A S | $7,010.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $6,206.23 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $3,920.09 | 2019-2025 | Invega Sustenna, Spravato |
| Vanda Pharmaceuticals INC. | $806.34 | 2024-2025 | Fanapt |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $267.37 | 2021-2022 | |
| Tris Pharma INC | $156.01 | 2023 | Dyanavel Xr |
| Harmony Biosciences LLC | $89.97 | 2023-2024 | Wakix |
| Idorsia Pharmaceuticals US INC | $38.16 | 2023 | Quviviq |
| Indivior INC. | $38.07 | 2019-2023 | Perseris |
| Lundbeck LLC | $35.32 | 2023 | Abilify Maintena |
| Ethicon US, LLC | $21.49 | 2021 | |
| Evofem Biosciences, INC. | $17.15 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Sureddi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.